Eli Lilly (LLY)

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

Beam Therapeutics' growing pipeline could reward patient investors.

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

It is definitely a strong contender.

Maybe you should, too.

BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.

IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?

Viking's latest program seeks to push the envelope in weight loss efficacy.

IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Novo Nordisk is finally getting one up on its biggest rival.

Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening.

The psychedelic drugmaker is being acquired.

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.

Investors need to ask tough questions before initiating a position in this biotech company.

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.

Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.

IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.

Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.

Bill Baruch chose Eli Lilly as his final trade, supported by Citigroup's analyst. Other experts recommended Vistra, Meta Platforms, and T. Rowe Price.